Thinly traded micro cap Sienna Biopharmaceuticals (SNNA -27.2%) is down on average volume following its announcement of topline data from a Phase 2b clinical trial evaluating SNA-120 (pegcantratinib) in patients with mild-to-moderate psoriasis with at least moderate pruritis (itchy skin).
The study failed to achieve the primary endpoint of the change from baseline to week 8 in a scale of pruritis severity called I-NRS. Specifically, patients treated with SNA-120 experienced a mean 4.3-point reduction in I-NRS compared to a 4.0-point reduction for vehicle (placebo) (p=0.244). The results were similar between the 0.05% and 0.5% strengths.
On a positive note, 27% of treated patients achieved a 75% reduction in symptoms (PASI 75) compared to 13% for vehicle (p=0.045).
No safety signals were observed.
A Phase 2 study in atopic dermatitis should launch in H2 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.